-- Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. -- Chime Biologics will ...

Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Not long ago, solving the crystal structure of a protein required an entire PhD. Growing crystals, collecting X-ray diffraction data, and interpreting electron density maps often took years of ...

HCW Biologics Inc. and WY Biotech Co., Ltd. have finalized a licensing agreement for the development and commercialization of HCW11-006, a novel immunotherapy targeting age-related diseases and cancer ...

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...

"Our vision is to turn the world's most powerful photosynthetic cell into a platform for scalable drug production that could ...

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the ...

The partnership pairs Novo Nordisk’s expertise in protein therapeutics with Vivtex’s gastrointestinal screening and formulation platform.